Home » Stocks » CNSP

CNS Pharmaceuticals, Inc. (CNSP)

Stock Price: $1.77 USD -0.07 (-3.80%)
Updated Oct 28, 2020 10:34 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 29.47M
Revenue (ttm) n/a
Net Income (ttm) -7.68M
Shares Out 16.65M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.77
Previous Close $1.84
Change ($) -0.07
Change (%) -3.80%
Day's Open 1.84
Day's Range 1.75 - 1.81
Day's Volume 6,654
52-Week Range 1.26 - 5.69

More Stats

Market Cap 29.47M
Enterprise Value 26.85M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.65M
Float 6.55M
EPS (basic) -0.50
EPS (diluted) -0.64
FCF / Share -0.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 85,382
Short Ratio 2.26
Short % of Float 1.30%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.29
Revenue n/a
Operating Income -7.66M
Net Income -7.68M
Free Cash Flow -7.48M
Net Cash 2.63M
Net Cash / Share 0.16
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -170.24%
ROE -374.22%
ROIC -2,263.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(436.72% upside)
Current: $1.77
Target: 9.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-3.83-0.88
Net Income-3.88-7.39
Shares Outstanding13.6510.51
Earnings Per Share-0.28-0.70
Operating Cash Flow-3.55-0.72
Capital Expenditures-0.02-
Free Cash Flow-3.57-0.72
Cash & Equivalents7.240.56
Total Debt-0.32
Net Cash / Debt7.240.24
Book Value7.60-0.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CNS Pharmaceuticals, Inc.
Country United States
Employees 3
CEO John M. Climaco

Stock Information

Ticker Symbol CNSP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CNSP
IPO Date November 8, 2019


CNS Pharmaceuticals, a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.